10 results on '"Watson, Anna"'
Search Results
2. Empagliflozin modulates renal sympathetic and heart rate baroreflexes in a rabbit model of diabetes
- Author
-
Gueguen, Cindy, Burke, Sandra L., Barzel, Benjamin, Eikelis, Nina, Watson, Anna M. D., Jha, Jay C., Jackson, Kristy L., Sata, Yusuke, Lim, Kyungjoon, Lambert, Gavin W., Jandeleit-Dahm, Karin A. M., Cooper, Mark E., Thomas, Merlin C., and Head, Geoffrey A.
- Published
- 2020
- Full Text
- View/download PDF
3. Disparate Effects of Diabetes and Hyperlipidemia on Experimental Kidney Disease.
- Author
-
Watson, Anna M. D., Gould, Eleanor A. M., Moody, Sarah C., Sivakumaran, Priyadharshini, Sourris, Karly C., Chow, Bryna S. M., Koïtka-Weber, Audrey, Allen, Terri J., Jandeleit-Dahm, Karin A. M., Cooper, Mark E., and Calkin, Anna C.
- Subjects
KNOCKOUT mice ,KIDNEY diseases ,DIABETIC nephropathies ,WESTERN diet ,GLYCOSYLATED hemoglobin ,RENIN-angiotensin system - Abstract
It is well established that diabetes is the major cause of chronic kidney disease worldwide. Both hyperglycemia, and more recently, advanced glycation endproducts, have been shown to play critical roles in the development of kidney disease. Moreover, the renin-angiotensin system along with growth factors and cytokines have also been shown to contribute to the onset and progression of diabetic kidney disease; however, the role of lipids in this context is poorly characterized. The current study aimed to compare the effect of 20 weeks of streptozotocin-induced diabetes or western diet feeding on kidney disease in two different mouse strains, C57BL/6 mice and hyperlipidemic apolipoprotein (apo) E knockout (KO) mice. Mice were fed a chow diet (control), a western diet (21% fat, 0.15% cholesterol) or were induced with streptozotocin-diabetes (55 mg/kg/day for 5 days) then fed a chow diet and followed for 20 weeks. The induction of diabetes was associated with a 3-fold elevation in glycated hemoglobin and an increase in kidney to body weight ratio regardless of strain (p < 0.0001). ApoE deficiency significantly increased plasma cholesterol and triglyceride levels and feeding of a western diet exacerbated these effects. Despite this, urinary albumin excretion (UAE) was elevated in diabetic mice to a similar extent in both strains (p < 0.0001) but no effect was seen with a western diet in either strain. Diabetes was also associated with extracellular matrix accumulation in both strains, and western diet feeding to a lesser extent in apoE KO mice. Consistent with this, an increase in renal mRNA expression of the fibrotic marker, fibronectin, was observed in diabetic C57BL/6 mice (p < 0.0001). In summary, these studies demonstrate disparate effects of diabetes and hyperlipidemia on kidney injury, with features of the diabetic milieu other than lipids suggested to play a more prominent role in driving renal pathology. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
4. Characterising an Alternative Murine Model of Diabetic Cardiomyopathy.
- Author
-
Tate, Mitchel, Prakoso, Darnel, Willis, Andrew M., Cheng Peng, Deo, Minh, Cheng Xue Qin, Walsh, Jesse L., Nash, David M., Cohen, Charles D., Rofe, Alex K., Sharma, Arpeeta, Kiriazis, Helen, Donner, Daniel G., De Haan, Judy B., Watson, Anna M. D., De Blasio, Miles J., and Ritchie, Rebecca H.
- Abstract
The increasing burden of heart failure globally can be partly attributed to the increased prevalence of diabetes, and the subsequent development of a distinct form of heart failure known as diabetic cardiomyopathy. Despite this, effective treatment options have remained elusive, due partly to the lack of an experimental model that adequately mimics human disease. In the current study, we combined three consecutive daily injections of low-dose streptozotocin with high-fat diet, in order to recapitulate the long-term complications of diabetes, with a specific focus on the diabetic heart. At 26 weeks of diabetes, several metabolic changes were observed including elevated blood glucose, glycated haemoglobin, plasma insulin and plasma C-peptide. Further analysis of organs commonly affected by diabetes revealed diabetic nephropathy, underlined by renal functional and structural abnormalities, as well as progressive liver damage. In addition, this protocol led to robust left ventricular diastolic dysfunction at 26 weeks with preserved systolic function, a key characteristic of patients with type 2 diabetes-induced cardiomyopathy. These observations corresponded with cardiac structural changes, namely an increase in myocardial fibrosis, as well as activation of several cardiac signalling pathways previously implicated in disease progression. It is hoped that development of an appropriate model will help to understand some the pathophysiological mechanisms underlying the accelerated progression of diabetic complications, leading ultimately to more efficacious treatment options. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
5. Diabetes and Hypertension Differentially Affect Renal Catecholamines and Renal Reactive Oxygen Species.
- Author
-
Watson, Anna M. D., Gould, Eleanor A. M., Penfold, Sally A., Lambert, Gavin W., Pratama, Putra Riza, Dai, Aozhi, Gray, Stephen P., Head, Geoffrey A., and Jandeleit-Dahm, Karin A.
- Subjects
DIABETES ,HYPERTENSION ,CATECHOLAMINES ,KIDNEY diseases ,REACTIVE oxygen species ,OXIDATIVE stress - Abstract
Patients with diabetic hypertensive nephropathy have accelerated disease progression. Diabetes and hypertension have both been associated with changes in renal catecholamines and reactive oxygen species. With a specific focus on renal catecholamines and oxidative stress we examined a combined model of hypertension and diabetes using normotensive BPN/3J and hypertensive BPH/2J Schlager mice. Induction of diabetes (5 × 55 mg/kg streptozotocin i.p.) did not change the hypertensive status of BPH/2J mice (telemetric 24 h avg. MAP, non-diabetic 131 ± 2 vs. diabetic 129 ± 1 mmHg, n.s at 9 weeks of study). Diabetes-associated albuminuria was higher in BPH/2J vs. diabetic BPN/3J (1205 + 196/-169 versus 496 + 67/-59 μg/24 h, p = 0.008). HPLC measurement of renal cortical norepinephrine and dopamine showed significantly greater levels in hypertensive mice whilst diabetes was associated with significantly lower catecholamine levels. Diabetic BPH/2J also had greater renal catecholamine levels than diabetic BPN/3J (diabetic: norepinephrine BPN/3J 40 ± 4, BPH/2J 91 ± 5, p = 0.010; dopamine: BPN/3J 2 ± 1; BPH/2J 3 ± 1 ng/mg total protein, p < 0.001 after 10 weeks of study). Diabetic BPH/2J showed greater cortical tubular immunostaining for monoamine oxidase A and cortical mitochondrial hydrogen peroxide formation was greater in both diabetic and non-diabetic BPH/2J. While cytosolic catalase activity was greater in non-diabetic BPH/2J it was significantly lower in diabetic BPH/2J (cytosolic: BPH/2J 127 ± 12 vs. 63 ± 6 nmol/min/ml, p < 0.001). We conclude that greater levels of renal norepinephrine and dopamine associated with hypertension, together with diabetes-associated compromised anti-oxidant systems, contribute to increased renal oxidative stress in diabetes and hypertension. Elevations in renal cortical catecholamines and reactive oxygen species have important therapeutic implications for hypertensive diabetic patients. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
6. Metabolic Karma-The Atherogenic Legacy of Diabetes: The 2017 Edwin Bierman Award Lecture.
- Author
-
Cooper, Mark Emmanuel, El-Osta, Assam, Allen, Terri Jean, Watson, Anna Margareta Dorothea, Thomas, Merlin Christopher, and Jandeleit-Dahm, Karin Agnes Maria
- Subjects
DIABETES ,CARDIOVASCULAR diseases ,HEART disease related mortality ,ATHEROSCLEROSIS ,OXIDATIVE stress ,HYPERGLYCEMIA - Abstract
Cardiovascular disease, despite all the recent advances in treatment of the various risk factors, remains the major cause of mortality in both type 1 and type 2 diabetes. Experimental models of diabetes-associated atherosclerosis, despite their limitations in recapitulating the human context, have assisted in the elucidation of molecular and cellular pathways implicated in the development and progression of macrovascular injury in diabetes. Our own studies have emphasized the role of oxidative stress and advanced glycation and identified potential targets for vasoprotective therapies in the setting of diabetes. Furthermore, it has been clearly shown that previous episodes of hyperglycemia play a key role in promoting end-organ injury in diabetes, as shown in clinical trials such as the UK Prospective Diabetes Study (UKPDS), Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation Observational Study (ADVANCE-ON), and the Diabetes Control and Complications Trial/ Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC). The cause of this phenomenon, known as metabolic memory, remains to be elucidated, but it appears that epigenetic pathways, including glucose-induced histone methylation, play a central role. Further delineation of these pathways and their link to not only glucose but also other factors implicated in vascular injury should lead to more rational, potentially more effective therapies to retard diabetes-associated cardiovascular disease. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
7. Corrigendum: Characterising an Alternative Murine Model of Diabetic Cardiomyopathy.
- Author
-
Tate, Mitchel, Prakoso, Darnel, Willis, Andrew M., Peng, Cheng, Deo, Minh, Qin, Cheng Xue, Walsh, Jesse L., Nash, David M., Cohen, Charles D., Rofe, Alex K., Sharma, Arpeeta, Kiriazis, Helen, Donner, Daniel G., De Haan, Judy B., Watson, Anna M. D., De Blasio, Miles J., and Ritchie, Rebecca H.
- Subjects
DIABETIC cardiomyopathy ,TYPE 2 diabetes ,ADIPOSE tissues ,GLUCOSE tolerance tests ,HIGH-fat diet - Abstract
By correcting the graphs, the actual outcomes for these graphs does not change the results or outcomes of the manuscript. Keywords: diabetes; type 2 diabetes; diabetic cardiomyopathy; cardiac; experimental model EN diabetes type 2 diabetes diabetic cardiomyopathy cardiac experimental model 1 2 2 08/23/21 20210819 NES 210819 In the original article, there was a mistake in Figures 1G and H as published. Diabetes, type 2 diabetes, diabetic cardiomyopathy, cardiac, experimental model. [Extracted from the article]
- Published
- 2021
- Full Text
- View/download PDF
8. Alagebrium Reduces Glomerular Fibrogenesis and Inflammation Beyond Preventing RAGE Activation in Diabetic Apolipoprotein E Knockout Mice.
- Author
-
Watson, Anna M. D., Gray, Stephen P., Li Jiaze, Soro-Paavonen, Aino, Wong, Benedict, Cooper, Mark E., Bierhaus, Angelika, Pickering, Raelene, Tikellis, Christos, Tsorotes, Despina, Thomas, Merlin C., and Jandeleit-Dahm, Karin A. M.
- Subjects
- *
ADVANCED glycation end-products , *DIABETIC nephropathies , *OXIDATIVE stress , *IMMUNOSUPPRESSIVE agents , *APOLIPOPROTEIN E , *DIABETES - Abstract
Advanced glycation end products (AGEs) are important mediators of diabetic nephropathy that act through the receptor for AGEs (RAGE), as well as other mechanisms, to promote renal inflammation and glomerulosclerosis. The relative contribution of RAGE-dependent and RAGE-independent signaling pathways has not been previously studied in vivo. In this study, diabetic RAGE apoE double-knockout (KO) mice with streptozotocin-induced diabetes were treated with the AGE inhibitor, alagebrium (1 mg/kg/day), or the ACE inhibitor, quinapril (30 mg/kg/day), for 20 weeks, and renal parameters were assessed. RAGE deletion attenuated mesangial expansion, glomerular matrix accumulation, and renal oxidative stress associated with 20 weeks of diabetes. By contrast, inflammation and AGE accumulation associated with diabetes was not prevented. However, treatment with alagebrium in diabetic RAGE apoE KO mice reduced renal AGE levels and further reduced glomerular matrix accumulation. In addition, even in the absence of RAGE expression, alagebrium attenuated cortical inflammation, as denoted by the reduced expression of monocyte chemoattractant protein-1, intracellular adhesion molecule-1, and the macrophage marker cluster of differentiation molecule 11b. These novel findings confirm the presence of important RAGE-independent as well as RAGE-dependent signaling pathways that may be activated in the kidney by AGEs. This has important implications for the design of optimal therapeutic strategies for the prevention of diabetic nephropathy. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
9. Receptor for Advanced Glycation End Products (RAGE) Deficiency Attenuates the Development of Atherosclerosis in Diabetes.
- Author
-
Soro-Paavonen, Aino, Watson, Anna M. D., Li, Jiaze, Paavonen, Karri, Koitka, Audrey, Calkin, Anna C., Barit, David, Coughlan, Melinda T., Drew, Brian G., Lancaster, Graeme I., Thomas, Merlin, Forbes, Josephine M., Nawroth, Peter P., Bierhaus, Angelika, Cooper, Mark E., and Jandeleit-Dahm, Karin A.
- Subjects
- *
ATHEROSCLEROSIS , *DIABETES , *BLOOD vessels , *LABORATORY mice , *STREPTOZOTOCIN , *ATHEROSCLEROTIC plaque , *LEUCOCYTES , *OXIDATIVE stress - Abstract
OBJECTIVE--Activation of the receptor for advanced glycation end products (RAGE) in diabetic vasculature is considered to be a key mediator of atherogenesis. This study examines the effects of deletion of RAGE on the development of atherosclerosis in the diabetic apoE[sup -/-] model of accelerated atherosclerosis. RESEARCH DESIGN AND METHODS--ApoE[sup -/-] and RAGE[sup -/-] apoE[sup -/-] double knockout mice were rendered diabetic with streptozotocin and followed for 20 weeks, at which time plaque accumulation was assessed by en face analysis. RESULTS--Although diabetic apoE[sup -/-] mice showed increased plaque accumulation (14.9 ± 1.7%), diabetic RAGE[sup -/-]apoE[sup -/-] mice had significantly reduced atherosclerotic plaque area (4.9 +0.4%) to levels not significantly different from control apoE[sup -/-] mice (4.3 ± 0.4%). These beneficial effects on the vasculature were associated with attenuation of leukocyte recruitment; decreased expression of proinflammatory mediators, including the nuclear factor-κB subunit p65, VCAM-1, and MCP-1; and reduced oxidative stress, as reflected by staining for nitrotyrosine and reduced expression of various NADPH oxidase subunits, gp91phox, p47phox, and rac-1. Both RAGE and RAGE ligands, including S100A8/A9, high mobility group box 1 (HMGB1), and the advanced glycation end product (AGE) carboxymethyllysine were increased in plaques from diabetic apoE[sup -/-] mice. Furthermore, the accumulation of AGEs and other ligands to RAGE was reduced in diabetic RAGE[sup -/-]apoE[sup -/-] mice. CONCLUSIONS--This study provides evidence for RAGE playing a central role in the development of accelerated atherosclerosis associated with diabetes. These findings emphasize the potential utility of strategies targeting RAGE activation in the prevention and treatment of diabetic macrovascular complications. Diabetes 57:2461-2469, 2008 [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
10. THE AGE/RAGE AXIS IN DIABETES-ACCELERATED ATHEROSCLEROSIS.
- Author
-
Jandeleit-Dahm, Karin, Watson, Anna, and Soro-Paavonen, Aino
- Subjects
- *
DIABETES , *ATHEROSCLEROSIS , *VASCULAR diseases , *CARRIER proteins , *TISSUE wounds , *TRANSGENIC mice - Abstract
1. There is increasing evidence that advanced glycation end-products (AGEs) and their interaction with the receptor RAGE play a pivotal role in atherosclerosis, in particular in the setting of diabetes. 2. Previous studies have shown that inhibition of AGE accumulation and RAGE expression in diabetes by either reduction of the formation of AGEs or cross-link breakers was associated with reduced atherosclerosis and renal disease. Advanced glycation end-products bind to RAGE, thereby leading to activation of a range of inflammatory and fibrotic pathways causing tissue injury. Different splice variants of RAGE exist, including a soluble form that lacks the intracellular domain and fails to induce signal transduction. Therapeutic approaches using soluble RAGE as a decoy binding protein for circulating AGE have been effective in preventing externally induced arterial injury and atherosclerosis in the absence and presence of diabetes. 3. In order to delineate the role of RAGE in vascular disease in more detail, it was necessary to create RAGE−/– mice, as well as transgenic mice overexpressing RAGE in endothelial cells. It was shown that RAGE overexpression was associated with increased vascular injury, nephropathy and retinopathy. 4. In contrast, RAGE deletion was associated with partial vascular protection, such as reduced neointima formation after arterial denudation, as well as protection from diabetic nephropathy. The present review summarizes the evidence for RAGE being a pro-inflammatory and pro-fibrotic receptor. 5. Further studies are needed to delineate the effect of RAGE deletion and overexpression in diabetic macrovascular disease. Based on these findings, RAGE could be a potential therapeutic target in combating inflammatory vascular diseases, including diabetes-associated atherosclerosis. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.